C difficile risk
Oral Bioavailability


CrCl ≥30 mL/minCrCl <30 mL/min1000mg IV Q24h500mg IV Q24h

If given after HDIf given with HD500mg IV Q24h1000mg IV

500mg IV Q24h

1g IV q24h

General Information

Approved Criteria:

  1. Documented infection due to ESBL- NOT cystitis
  2. Rapid diagnostic confirmed bacteremia with E.coli OR Klebsiella PLUS High Risk (ESBL Risk Score ≥2) AND Critically Ill (Pitt ≥4)
  3. Ordered by Infectious Disease/Antimicrobial Stewardship Provider
  4. NOT Approved for Preoperative Use at Prisma Health

NOT APPROVED for Preoperative Use at Prisma Health

Targeted therapy of ESBL infections and other resistant gram negative infections.

Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity.

  • Immediate and delayed-type allergy

  • GI disturbance

  • Cytopenias, eosinophilia, positive Coombs

  • Liver enzyme abnormalities

  • Seizure risk lower than other carbapenems

Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 4 hours

Biliary penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic